MicroShunt Offers Sustained Reduction in IOP in Patients With Glaucoma

Why It Matters

Sustained IOP reduction with fewer medications offers a safer, cost‑effective surgical option, potentially reshaping glaucoma management and reimbursement models.

Key Takeaways

• IOP dropped from 24.8 to 9.6 mmHg post‑op day 1
• Four‑year IOP averaged 13.7 mmHg, staying stable
• Medication use fell from 2.4 to 0.3 drops
• Complete success 54% at target 6‑21 mmHg after four years
• Study of 1001 eyes confirms durable MicroShunt efficacy

Pulse Analysis

Glaucoma remains the second leading cause of irreversible blindness worldwide, and lowering intraocular pressure (IOP) is the only proven strategy to slow optic‑nerve damage. Conventional filtration surgery such as trabeculectomy has long been the gold standard, yet it carries risks of hypotony, bleb leaks and postoperative scarring that can jeopardize visual outcomes. In recent years, minimally invasive bleb surgery (MIBS) devices have emerged to bridge the gap between medication‑only therapy and full‑scale filtration, offering a smaller conjunctival incision and a more predictable healing profile. The PreserFlo MicroShunt, a 70‑micron silicone tube with a porous plate, exemplifies this shift toward less traumatic IOP control.

A single‑center retrospective series published in Graefe’s Archive tracked 1,001 eyes over six years, revealing a mean IOP reduction from 24.8 mmHg pre‑op to 9.6 mmHg on day one and a sustained 13.7 mmHg at four years. Medication burden fell dramatically, from an average of 2.4 drops to just 0.3, and complete success—defined by target IOP ≤21 mmHg—reached 54% after four years. These outcomes compare favorably with published trabeculectomy series, especially considering the lower complication profile reported for the MicroShunt, positioning it as a viable first‑line surgical option for both standalone and combined cataract procedures.

For ophthalmology practices, the durability of IOP control translates into fewer follow‑up interventions and reduced long‑term pharmacy costs, factors that resonate with value‑based reimbursement models in the United States. While the device’s list price hovers around $2,500 per unit, the net cost of care may be offset by decreased medication usage and fewer revision surgeries. As real‑world evidence accumulates, insurers are likely to broaden coverage, accelerating adoption across community and academic centers. Ongoing trials exploring MicroShunt performance in diverse ethnic cohorts and its impact on visual field progression will further define its role in the glaucoma treatment algorithm.